Team:UCLondon/Team

From 2012e.igem.org

(Difference between revisions)
(Company Timeline)
(Board of Advisors)
 
(5 intermediate revisions not shown)
Line 47: Line 47:
{{:Team:UCLondon/Templates/Team-Advisor |class=advisors|picture=<html><img src="https://dl.dropbox.com/u/45600819/igemewiki%20team%20photos/advisors/c.jpg" height="130" width="168"/></html>|name=Henry Taunt|position=PhD Candidate of Therapeutic Proteins in Algal Chloroplast|description='''Henry''' is the alpha beta user and the instructor of the first ever research that triggers the emergence of CUO. His PhD is focused on utilizing <html><em>C. reinhardtii</em></html> as an expression platform for therapeutic proteins.  In particular, he is investigating a potential novel class of antibiotics known as bacteriophage endolysins.  These are lytic enzymes from bacterial specific viruses that enable the viral particles to escape the bacterial cell at the end of their life cycle.  This is done by breaking apart the peptidoglycan cell wall.  He has cloned the gene that encodes one of these enzymes into the <html><em>C. reinhardtii</em></html> chloroplast, and shown that the enzyme produced is able to specifically attack a penicillin-resistant human pathogen.  At present, he is attempting to purify and characterize this lysin, as well as beginning investigations into two more lysins specific to human pathogens.}}
{{:Team:UCLondon/Templates/Team-Advisor |class=advisors|picture=<html><img src="https://dl.dropbox.com/u/45600819/igemewiki%20team%20photos/advisors/c.jpg" height="130" width="168"/></html>|name=Henry Taunt|position=PhD Candidate of Therapeutic Proteins in Algal Chloroplast|description='''Henry''' is the alpha beta user and the instructor of the first ever research that triggers the emergence of CUO. His PhD is focused on utilizing <html><em>C. reinhardtii</em></html> as an expression platform for therapeutic proteins.  In particular, he is investigating a potential novel class of antibiotics known as bacteriophage endolysins.  These are lytic enzymes from bacterial specific viruses that enable the viral particles to escape the bacterial cell at the end of their life cycle.  This is done by breaking apart the peptidoglycan cell wall.  He has cloned the gene that encodes one of these enzymes into the <html><em>C. reinhardtii</em></html> chloroplast, and shown that the enzyme produced is able to specifically attack a penicillin-resistant human pathogen.  At present, he is attempting to purify and characterize this lysin, as well as beginning investigations into two more lysins specific to human pathogens.}}
 +
 +
 +
{{:Team:UCLondon/Templates/Team-Advisor |class=advisors|picture=<html><img src="https://dl.dropbox.com/u/3703109/igeme/uditization/devaki-ramachandran.jpg" height="130" width="168" style=""/></html>|name=Devaki Ramachandran|position=Industrial Bioinformatician|description=Devaki Possesses an outstanding record for achievements and experiences in academic institutions such as the Singapore Institute for Clinical Sciences as well as industrial key players such as Eli Lilly, Devaki has knowledge of both the technical and commercial aspects of running such an operation and is a great boost to the team.}}
==Company Timeline==
==Company Timeline==

Latest revision as of 20:02, 21 January 2013

Meet the Team!

Board of Directors

Board of Advisors


Company Timeline

Click Here

Click the button to see the work completed by each team member